News
March 11, 2011

Supreme Court Lets So-Called "Reverse Payment" Stand

Summary: On March 7, 2011, the U.S. Supreme Court denied a petition for a writ of certiorari filed by various drug purchasers in which they asked the Court to review so-called reverse payments, an arrangement that settles patent litigation brought by brand-name drug manufacturers against generic manufacturers. Under a so-called reverse payment arrangement, the brand-name manufacturer makes a payment to the generic manufacturer in consideration for the generic manufacturer’s agreement not to produce the challenged product.

The Court’s denial let stand a Second Circuit decision that rejected antitrust claims based on a settlement between Bayer AG, the owner of a patent for ciprofloxacin (“Cipro”), and Barr Laboratories, Inc., a generic manufacturer that had challenged the patent. The attached Client Alert provides the background leading up to, and the significance of, the Supreme Court’s denial.

People

Subscribe
Subscribe Link

Email Disclaimer